Your browser doesn't support javascript.
loading
Development and validation of a nomogram for predicting cancer-specific survival in small-bowel adenocarcinoma patients using the SEER database.
Xu, Duogang; He, Yulei; Liao, Changkang; Tan, Jing.
Afiliação
  • Xu D; Department of General Surgery, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, China.
  • He Y; Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Yunnan University of Chinese Medicine, Kunming, China.
  • Liao C; The First School of Clinical Medicine, Yunnan University of Chinese Medicine, Kunming, China.
  • Tan J; Department of General Surgery, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, China.
World J Surg Oncol ; 22(1): 151, 2024 Jun 07.
Article em En | MEDLINE | ID: mdl-38849854
ABSTRACT

BACKGROUND:

Small bowel adenocarcinoma (SBA) is a rare gastrointestinal malignancy forwhich survival is hampered by late diagnosis, complex responses to treatment, and poor prognosis. Accurate prognostic tools are crucial for optimizing treatment strategies and improving patient outcomes. This study aimed to develop and validate a nomogram based on the Surveillance, Epidemiology, and End Results (SEER) database to predict cancer-specific survival (CSS) in patients with SBA and compare it to traditional American Joint Committee on Cancer (AJCC) staging.

METHODS:

We analyzed data from 2,064 patients diagnosed with SBA between 2010 and 2020 from the SEER database. Patients were randomly assigned to training and validation cohorts (73 ratio). Kaplan‒Meier survival analysis, Cox multivariate regression, and nomograms were constructed for analysis of 3-year and 5-year CSS. The performance of the nomograms was evaluated using Harrell's concordance index (C-index), the area under the receiver operating characteristic (ROC) curve, calibration curves, decision curve analysis (DCA), net reclassification improvement (NRI), and integrated discrimination improvement (IDI).

RESULTS:

Multivariate Cox regression identified sex, age at diagnosis, marital status, tumor site, pathological grade, T stage, N stage, M stage, surgery, retrieval of regional lymph nodes (RORLN), and chemotherapy as independent covariates associated with CSS. In both the training and validation cohorts, the developed nomograms demonstrated superior performance to that of the AJCC staging system, with C-indices of 0.764 and 0.759, respectively. The area under the curve (AUC) values obtained by ROC analysis for 3-year and 5-year CSS prediction significantly surpassed those of the AJCC model. The nomograms were validated using calibration and decision curves, confirming their clinical utility and superior predictive accuracy. The NRI and IDI indicated the enhanced predictive capability of the nomogram model.

CONCLUSION:

The SEER-based nomogram offers a significantly superior ability to predict CSS in SBA patients, supporting its potential application in clinical decision-making and personalized approaches to managing SBA to improve survival outcomes.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Adenocarcinoma / Programa de SEER / Nomogramas / Neoplasias Intestinais Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: World J Surg Oncol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Adenocarcinoma / Programa de SEER / Nomogramas / Neoplasias Intestinais Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: World J Surg Oncol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China